Diagnostic Accuracy of the Mean Platelet Volume in the Prediction of Upper Urinary Tract Infections

2020 ◽  
Vol 66 (03/2020) ◽  
Author(s):  
Şule Gökçe ◽  
Zafer Kurugöl
Author(s):  
Edyta Cichocka ◽  
Michał Jagusiewicz ◽  
Janusz Gumprecht

Introduction: Sexual dysfunctions (SD) are chronic complications that can develop due to vascular complications or autonomic neuropathy. Additionally, such complications can be of hormonal, infectious or psychogenic etiology. Objectives: The aim of study was to assess the sexual function and acceptance of the chronic disease in young sexually active women with type 1 diabetes (T1DM). Materials and methods: A total of 169 female patients with T1DM completed two standardized questionnaires, the Female Sexual Function Index (FSFI) and the Acceptance of Illness Scale (AIS). Other medical data were collected from medical history. Results: The mean FSFI score was 27.96 ± 5.00, and the mean AIS score was 29.67 ± 8.28. The score < 26 points in FSFI was obtained by 28.7% of patients. Analysis of correlation between the FSFI and the AIS showed that the higher the score on the FSFI, the higher the score on the AIS. Patients who underwent regular physical activity (55%) had a significantly higher acceptance of the disease (p = 0.0026) and reported painful intercourse significantly less frequently (p = 0.01). The value of HbA1c in the study group was 7.31 ± 1.25%. Patients with poorer glycemic control (HbA1c > 8%) obtained significantly lower scores on the FSFI (p = 0.03), whereas no differences were found on the AIS. Diabetes-related complications were observed in 25.5% of patients. The presence of chronic complications did not affect the results of the FSFI or the AIS. Patients with diabetes and hypertension had poorer functioning in the sexual sphere and had significantly lower scores on the FSFI. Past or present history of depression was reported by 36% of patients and also negatively affected acceptance of diabetes (p = 0.0015). Patients who reported recurrent urinary tract infections (17%) achieved significantly lower scores on the FSFI (p = 0.03) and showed that sex-related pain was significantly more prevalent (p = 0.02). In the case of the statement related to the embarrassment of people around the patient due to diabetes, patients with lower scores complained of SD significantly more often (p = 0.0033). Past deliveries, the type of labor, the use of contraceptives or the number of sexual partners had no influence on the overall assessment in both scales. However, in terms of desire, women who had delivered obtained higher scores (p = 0.0021). Conclusion: SD in women with T1DM may result from diabetes-related complications, hormonal disorders or recurrent genital or urinary tract infections. However, they usually have a psychological basis due to the lack of acceptance of the problems related to the treatment of diabetes.


2007 ◽  
Vol 90 (4) ◽  
pp. 448-449 ◽  
Author(s):  
A Garoufi ◽  
K Voutsioti ◽  
H Tsapra ◽  
Th Karpathios ◽  
PM Zeis

2015 ◽  
Vol 95 (2) ◽  
pp. 167-176 ◽  
Author(s):  
Florian M.E. Wagenlehner ◽  
Stefania Ballarini ◽  
Adrian Pilatz ◽  
Wolfgang Weidner ◽  
Lorenz Lehr ◽  
...  

Background: One strategy for managing recurrent uncomplicated urinary tract infections (UTIs) is prevention. This study tested OM-89S, a lyophilized lysate of 18 Escherichia coli strains manufactured using a modified lytic process. Methods: This was a randomized, double-blind trial in 451 female subjects with recurrent uncomplicated UTIs. Period 1 of the study tested 6 mg of OM-89S versus placebo (3 months), plus a 3-month observation. Period 2 of the study was a 3-month treatment period (each monthly cycle consisted of 6 mg of OM-89S daily for 10 days and placebo for 20 days, vs. 50 mg nitrofurantoin daily for 30 days), plus a 3-month observation. Results: There was no difference in the mean rate of UTI episodes between the OM-89S (0.66 ± 0.93) and placebo groups (0.63 ± 0.86; p = 0.95) in period 1. Similar findings were obtained for period 2. OM-89S was well-tolerated. Conclusions: Our results did not demonstrate a preventive effect of OM-89S compared to placebo. This may be due to the low number of UTIs that occurred during the study, the high number of protocol violations, and/or the modified manufacturing process used for OM-89S.


2020 ◽  
Vol 9 (4) ◽  
pp. 37-40
Author(s):  
Adel S. Al-Shukri ◽  
Elena E. Zakharevich

To evaluate the efficacy and safety of the use of the drug Hileflox 750 (levofloxacin) in the treatment of uncomplicated infections of the upper urinary tract (pyelonephritis). 46 patients (9 men and 37 women) with uncomplicated pyelonephritis were observed. All patients were treated with Hileflox 750 mg orally once a day for 5 days. The drug showed high antibacterial activity, clinical efficacy and good tolerance. During follow-up for 6 months, not one patient showed abnormalities in laboratory tests, the development of complications or relapses of the disease. Conclusions: the results of the study showed the feasibility and effectiveness of the use of the drug Hayleflox 750 for the treatment of uncomplicated pyelonephritis in monotherapy.


Author(s):  
Arjun S. Chanmugam ◽  
Gino Scalabrini

Urinary tract infections (UTIs) refer to a urine culture yielding a minimum of 100 to 10,000 bacteria units/mm of urine usually from a clean catch midstream sample. This can result from infection of the lower urinary tract involving the bladder (cystitis) or an infection of the upper urinary tract involving the kidneys (pyelonephritis). Uncomplicated UTIs occur in healthy, pre-menopausal, non-pregnant women with a normal urinary tract who have a high likelihood to respond favorably to treatment, but consider local antibiotic resistance patterns. Complicated UTIs occur in women with coexisting pathology, anatomical abnormality, underlying comorbidity, or immunocompromise. Untreated UTIs can progress to pyelonephritis and urosepsis. Asymptomatic bacteriuria for pregnant women can progress very quickly; pyelonephritis carries increased risk of perinatal and neonatal mortality. Pregnant patients should be treated with cephalexin, amoxicillin, or amoxicillin-clavulanic acid (avoiding fluoroquinolones).


1997 ◽  
Vol 22 (12) ◽  
pp. 838-843 ◽  
Author(s):  
BRUNO BAGNI ◽  
PIERGIUSEPPE ORSOLON ◽  
ANDREA FATTORI ◽  
UGO PAOLO GUERRA

Sign in / Sign up

Export Citation Format

Share Document